Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8633179 | 0.84 | CYP3A4 (0.40) | SLC6A3KDM4EPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL9025789 | 0.84 | SLC6A3 (0.37) | SLC6A3KDM4EPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL9025658 | 0.83 | IDO1 (0.38) | SLC6A3KDM4EPKMIDO1TDO2 | |
| SCHEMBL8634063 | 0.83 | FFAR2 (0.38) | KDM4EPKMALDH1A1LMNAHPGD | |
| SCHEMBL9026742 | 0.83 | ATM (0.38) | SLC6A3KDM4EPKMIDO1TDO2 | |
| SCHEMBL8683323 | 0.82 | KDM4E (0.43) | SLC6A3KDM4EPKMALDH1A1LMNA | |
| SCHEMBL8635755 | 0.82 | SMN1; SMN2 (0.51) | SLC6A3KDM4ESMN1; SMN2LMNABRD4 | |
| SCHEMBL8632333 | 0.82 | ADRB1 (0.41) | SLC6A3KDM4ELMNABRD4CREBBP | |
| SCHEMBL8630297 | 0.82 | PFKFB3 (0.38) | SLC6A3KDM4EPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL9026983 | 0.82 | SLC6A3 (0.36) | SLC6A3KDM4EALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712299-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | ASTRA AKTIEBOLAG (SE) | 1998-01-27 | — | — | US | claimed |
| EP-0707574-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001968-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | claimed |
| EP-2566856-B1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | UNIV ILLINOIS (US) | 2017-02-01 | — | — | EP | disclosed |
| US-8957086-B2 | Compounds and methods of treating brain disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957086-B2 | Compounds and methods of treating brain disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957086-B2 | Compounds and methods of treating brain disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014013338-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SGC PHARMA, INC. (CA) | 2014-01-23 | — | — | WO | disclosed |
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THATCHER GREGORY R J (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THATCHER GREGORY R J (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THATCHER GREGORY R J (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2566856-A2 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | The Board of Trustees of the University of Illinois (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140198-A2 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140198-A2 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-5712299-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | ASTRA AKTIEBOLAG (SE) | 1998-01-27 | — | — | US | disclosed |
| EP-0707574-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001968-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131099-A1 | COMPOUNDS AND METHODS OF TREATING BRAIN DISORDERS | NLN, PYGB, OTC | SLC6A3 59/4885KDM4E 3944/4885PKM 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.